Both the systemic and the tumor-direct effects of dapagliflozin are being investigated in a phase 1 study in hyperinsulinemic women with HER2-negative breast cancer undergoing neoadjuvant treatment (NCT05989347). This evidence concerns the gene ERBB2 and breast cancer.